Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai to Form Corporate VC in Boston to Drive Innovation
June 28, 2023
- UBE, IPSC Startup Grab US Orphan Tag for IPF Therapy
June 28, 2023
- Rexulti Makes Mark in Japan PIII Study for Alzheimer’s Agitation: Otsuka
June 28, 2023
- Merck Biopharma, Pfizer Japan to End Bavencio Copromotion
June 28, 2023
- Amgen Japan to Cut 30 Jobs in Evenity Sales Unit as It Rejigs Organization
June 27, 2023
- Japan Approves Novartis’ Gene Therapy Luxturna for Rare Eye Disease
June 27, 2023
- Lonsurf-Bevacizumab Combo Nabs EU Panel Nod for Colorectal Cancer
June 27, 2023
- Shionogi Snaps Up Qpex to Boost Antimicrobial Pipeline
June 27, 2023
- Zenyaku Kogyo Bags Japan Rights to Singapore Firm’s Eczema Med
June 26, 2023
- Veritas, Takeda Link Up for mRNA-Targeted Drug Discovery against Genetic Disorders
June 26, 2023
- Japan Pharma Market Projected to Grow 0.5-1.5% through FY2027: IQVIA
June 26, 2023
- Nobelpharma Grants Authorized Generic Rights to Japanese Firm
June 26, 2023
- Shionogi CEO Hauls In 292 Million Yen after Record Year
June 26, 2023
- Kris Sisneros Takes Helm at LEO Pharma Japan
June 23, 2023
- Gilead Completes Marketing Authorization Transfer for Yescarta in Japan
June 23, 2023
- Astellas Chairman Snags 452 Million Yen in FY2022: Securities Report
June 23, 2023
- Combined Sales of 26 Japan Drug Makers Up 13.6% in FY2022 on Global Growth, COVID Demand
June 22, 2023
- Nippon Shinyaku Files Jazz’s High-Risk AML Drug in Japan
June 22, 2023
- 4 Eisai Execs Earn 100 Million Yen-Plus Pay, CEO Takes Home 157 Million Yen
June 22, 2023
- Global Pharma Market Grows 8.3% in 2022, Humira Top-Seller Drug: IQVIA
June 21, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…